Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25106841 | 0.80 | CYP3A4 (0.30) | CYP3A4TSHRTDP1 | |
| SCHEMBL21487341 | 0.72 | GPR35 (0.46) | TDP1ALDH1A1KDM4EMAPTTTR | |
| SCHEMBL17744522 | 0.69 | ALDH1A1 (0.60) | CYP3A4TSHRTDP1ALDH1A1KDM4E | |
| SCHEMBL18834055 | 0.68 | ALOX15 (0.46) | GAAALOX15ALOX12 | |
| SCHEMBL17231836 | 0.68 | ALDH1A1 (0.48) | CYP3A4TSHRTDP1ALDH1A1KDM4E | |
| SCHEMBL21695780 | 0.68 | GAA (0.50) | CYP3A4TSHRTDP1ALDH1A1KDM4E | |
| SCHEMBL270714 | 0.68 | CYP3A4 (0.50) | CYP3A4TSHRTDP1ALDH1A1MAPT | |
| SCHEMBL7724850 | 0.68 | CYP3A4 (0.65) | CYP3A4TSHRTDP1ALDH1A1KDM4E | |
| SCHEMBL11839854 | 0.66 | — | — | |
| SCHEMBL30774846 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| EP-4218766-A1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | Incyte Holdings Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3674302-B1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE HOLDINGS CORP (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112312914-A | Therapeutic agent for inflammatory disease, autoimmune disease, fibrotic disease, and cancer disease | 明治制果药业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| EP-3674302-A1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | Incyte Corporation (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-3134403-B1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE CORP (US) | 2020-02-12 | — | — | EP | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | REN, CYP11B1, CYP11B2 | CYP3A4 123/4885TSHR 1710/4885TDP1 4735/4885 |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | CYP3A4 55/4885TSHR 1411/4885TDP1 4682/4885 |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | CCR1, SSB, C5 | CYP3A4 2270/4885TSHR 1153/4885TDP1 4442/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | CYP3A4 2270/4885TSHR 1153/4885TDP1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.